HER2 was overexpressed (score 3+) in 7.0% (65/929) of GC cases and 14.6% (78/534) of GEJ adenocarcinoma cases (Figure 1A). This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.